The company developed the instrument using in-licensed technology coupled with its own chemistry and other technology for exosomal protein analysis.
The deal follows a June agreement under which Exosome is developing an exosomal RNA sequencing platform with Takeda.
The partners will develop a biomarker discovery platform based on Exosome Diagnostics' exosomal RNA sequencing technology.
The results support the tests potential to more specifically predict high-risk prostate cancers, and lower the number of unnecessary prostate biopsies.
The company said it would use the funds to support growth in its commercial diagnostics, regulatory, and companion diagnostics divisions.
The firm is also expanding its diagnostics sales force and adding development and regulatory staff ahead of near-term product launches.
The funding coincides with publication of reports from the Extracellular RNA Consortium outlining growth and challenges in exosomal RNA-based diagnostics.
In Science this week: metagenomic-based technique for determining protein structure, and more.
An academic laments the rise of narcissism in the sciences, the Guardian reports.
Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.
The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.